The treatment of perceptual disturbances in schizophrenia with naloxone hydrochloride.
The authors treated 12 schizophrenic patients who had overt hallucinatory symptoms with intravenously administered naloxone hydrochloride, a narcotic antagonist purported to have antihallucinatory properties. They found no evidence of the effectiveness of naloxone in preventing hallucinations over that of placebo when administered in a randomized, double-blind fashion.
D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D006212:Hallucinations / Q000188:drug therapy*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000008:administration & dosage / Q000627:therapeutic use*; D010865:Pilot Projects; D010919:Placebos; D012559:Schizophrenia / Q000188:drug therapy; D012565:Schizophrenic Psychology
D010919:Placebos; D009270:Naloxone